Orum Therapeutics to Present Preclinical Data for ORM-5029, a Novel Antibody Neodegrader Conjugate, at the AACR Annual Meeting 2022

On March 8, 2022 Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders, reported that the Company will present preclinical data for ORM-5029 at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 taking place April 8-13 virtually and in-person at the Ernest N. Morial Convention Center in New Orleans (Press release, Orum Therapeutics, MAR 8, 2022, View Source [SID1234609716]). Orum is developing ORM-5029 as a potential first-in-class targeted protein degrader therapy for HER2-expressing breast cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Poster Title: ORM-5029: A first-in-class targeted protein degradation therapy using antibody neodegrader conjugate (AnDC) for HER2-expressing breast cancer
Date and Time: Wednesday, April 13, 9:00 AM – 12:30 PM EDT
Virtual E-Poster Viewing: April 8 to July 13
Session Category: Experimental and Molecular Therapeutics
Session Title: Emerging New Anticancer Agents
Session Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 22
Poster Board Number: 7
Abstract number: 3933

About Orum’s AnDC Platform

Orum’s Antibody neoDegrader Conjugate (AnDC) platform is built on novel targeted protein degrader (TPD) combined with the precise tumor cell delivery mechanisms of antibodies to generate innovative, first-in-class cell-specific TPD for the treatment of cancer. The company has developed new molecular glue degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, neoDegraders are designed to be delivered specifically to cancer cells and degrade the intracellular target protein and cause tumor cell death.